Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACOG Alpha Cognition	$8.00 -19.9%	$9.67	$3.75 ▼ $11.54	$160.04M	2.72	47,379 shs	233,385 shs
ENTA Enanta Pharmaceuticals	$7.74 +2.1%	$7.39	$4.09 ▼ $13.43	$162.03M	0.88	175,351 shs	130,611 shs
LIMN Liminatus Pharma	$4.12 -6.4%	$0.00	$4.08 ▼ $33.66	$114.46M	N/A	983,772 shs	1.05 million shs
MURA Mural Oncology	$1.77 -1.1%	$2.34	$0.95 ▼ $4.74	$31.01M	3	276,179 shs	106,238 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACOG Alpha Cognition	-19.92%	-12.38%	-23.08%	-7.51%	+799,999,900.00%
ENTA Enanta Pharmaceuticals	+2.11%	+10.73%	+17.45%	+34.61%	-33.10%
LIMN Liminatus Pharma	-6.36%	-14.70%	-26.30%	+411,999,900.00%	+411,999,900.00%
MURA Mural Oncology	-1.12%	+5.36%	-28.92%	-33.21%	-44.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACOG Alpha Cognition	1.9642 of 5 stars	3.5	0.0	0.0	0.0	3.4	0.8	0.0
ENTA Enanta Pharmaceuticals	3.7664 of 5 stars	3.5	0.0	0.0	4.7	2.5	2.5	0.0
LIMN Liminatus Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MURA Mural Oncology	3.188 of 5 stars	3.3	3.0	0.0	0.0	2.7	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACOG Alpha Cognition	3.00	Buy	$20.00	150.00% Upside
ENTA Enanta Pharmaceuticals	3.00	Buy	$21.67	179.93% Upside
LIMN Liminatus Pharma	0.00	N/A	N/A	N/A
MURA Mural Oncology	2.50	Moderate Buy	$12.00	577.97% Upside

Current Analyst Ratings Breakdown

Latest MURA, ACOG, LIMN, and ENTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	ENTA Enanta Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$24.00 ➝ $25.00
7/28/2025	ENTA Enanta Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00
6/3/2025	ENTA Enanta Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$23.00 ➝ $24.00
5/16/2025	ACOG Alpha Cognition	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACOG Alpha Cognition	N/A	N/A	N/A	N/A	$2.59 per share	N/A
ENTA Enanta Pharmaceuticals	$67.64M	2.45	N/A	N/A	$3.71 per share	2.09
LIMN Liminatus Pharma	N/A	N/A	N/A	N/A	N/A	N/A
MURA Mural Oncology	N/A	N/A	N/A	N/A	$3.39 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACOG Alpha Cognition	-$14.64M	-$1.20	N/A	∞	N/A	N/A	-65.83%	-48.21%	N/A
ENTA Enanta Pharmaceuticals	-$116.04M	-$4.32	N/A	N/A	N/A	-141.98%	-89.02%	-27.28%	N/A
LIMN Liminatus Pharma	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MURA Mural Oncology	-$128.51M	-$8.59	N/A	N/A	N/A	N/A	-107.76%	-87.57%	N/A

Latest MURA, ACOG, LIMN, and ENTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ACOG Alpha Cognition	-$0.84	-$0.65	+$0.19	-$0.65	$2.32 million	N/A
8/11/2025	Q3 2025	ENTA Enanta Pharmaceuticals	-$1.25	-$0.85	+$0.40	-$0.85	$16.21 million	$18.31 million
8/4/2025	Q2 2025	MURA Mural Oncology	-$1.13	-$1.77	-$0.64	-$2.78	N/A	N/A
5/15/2025	Q1 2025	ACOG Alpha Cognition	-$0.58	-$0.20	+$0.38	-$0.13	$0.50 million	$2.93 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACOG Alpha Cognition	N/A	N/A	N/A	N/A	N/A
ENTA Enanta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LIMN Liminatus Pharma	N/A	N/A	N/A	N/A	N/A
MURA Mural Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACOG Alpha Cognition	N/A	17.14	16.83
ENTA Enanta Pharmaceuticals	N/A	5.00	5.29
LIMN Liminatus Pharma	N/A	N/A	N/A
MURA Mural Oncology	N/A	2.87	2.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACOG Alpha Cognition	N/A
ENTA Enanta Pharmaceuticals	94.99%
LIMN Liminatus Pharma	N/A
MURA Mural Oncology	80.21%

Insider Ownership

Company	Insider Ownership
ACOG Alpha Cognition	14.00%
ENTA Enanta Pharmaceuticals	13.89%
LIMN Liminatus Pharma	N/A
MURA Mural Oncology	2.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACOG Alpha Cognition	N/A	16.02 million	13.78 million	N/A
ENTA Enanta Pharmaceuticals	160	21.38 million	18.41 million	Optionable
LIMN Liminatus Pharma	N/A	26.01 million	N/A	N/A
MURA Mural Oncology	119	17.32 million	16.94 million	Optionable

MURA, ACOG, LIMN, and ENTA Headlines

Recent News About These Companies

Why some in Columbia cared so much about saving Hunter-Gatherer’s bricks & mural

August 14 at 10:03 AM | thestate.comT

Mural Oncology (MURA) to Release Quarterly Earnings on Tuesday

August 11, 2025 | americanbankingnews.com

Mural Oncology (NASDAQ:MURA) Cut to Strong Sell at Wall Street Zen

August 10, 2025 | americanbankingnews.com

Colourful mural celebrates 10 years of cancer care at WWL

August 4, 2025 | msn.com

Mural Oncology Announces Second Quarter Financial Results and Provides Business Update

August 4, 2025 | globenewswire.com

Artists help pupils and centre users create murals

August 3, 2025 | msn.com

Baltimore honors Henrietta Lacks with community-painted mural

August 2, 2025 | msn.com

Baltimore community comes together to complete Henrietta Lacks mural

August 2, 2025 | wmar2news.comW

Community news: Mural walk, health fair, digital skill lessons

July 28, 2025 | chicagotribune.com

Downtown Raleigh’s history unfolds in a sprawling new mural. Who is on it?

July 28, 2025 | msn.com

New mural inspires student growth on the Eastern Shore

July 28, 2025 | msn.com

Can Mural Oncology (NASDAQ:MURA) Afford To Invest In Growth?

July 23, 2025 | finance.yahoo.com

Minneapolis muralist honors Tuskegee airmen

July 19, 2025 | msn.com

Mural Oncology, Inc.: Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones - FinanzNachrichten.de

July 8, 2025 | finanznachrichten.de

Demolition threatens breast cancer mural in 12 Points community

July 5, 2025 | wthitv.comW

Building that features the PINK of Terre Haute wings mural to be demolished

July 4, 2025 | msn.com

'Vibrancy': New murals proposed for Downtown Peoria parking decks

July 3, 2025 | msn.com

Form 8.3 - The Vanguard Group, Inc.: Mural Oncology plc

June 16, 2025 | markets.businessinsider.com

BlackRock discloses 1.64% stake in Mural Oncology

June 13, 2025 | investing.com

Form 8.3 - The Vanguard Group, Inc.: Mural Oncology plc

June 13, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MURA, ACOG, LIMN, and ENTA Company Descriptions

Alpha Cognition NASDAQ:ACOG

$8.00 -1.99 (-19.92%)

As of 08/14/2025 04:00 PM Eastern

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Enanta Pharmaceuticals NASDAQ:ENTA

$7.74 +0.16 (+2.11%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$7.74 0.00 (0.00%)

As of 08/14/2025 04:20 PM Eastern

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Liminatus Pharma NASDAQ:LIMN

$4.12 -0.28 (-6.36%)

As of 08/14/2025 04:00 PM Eastern

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

Mural Oncology NASDAQ:MURA

$1.77 -0.02 (-1.12%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.76 -0.02 (-0.85%)

As of 07:51 AM Eastern

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time